by EPI Health | Aug 31, 2021 | Press Release
PRESS RELEASE for distribution August 31, 2021, 08:00 ET Results of an expert roundtable meeting now published in Journal of Drugs in Dermatology concluded that dermatologists need to place greater emphasis on managing persistent facial erythema (or neurovascular...
by EPI Health | Jul 19, 2021 | Press Release
PRESS RELEASE for distribution July 19, 2021, 08:00 ET Now available: Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) once-daily topical treatment of plaque psoriasis in adults 18 years of age or older introduces use of PAD™...
by EPI Health | Jul 12, 2021 | Press Release
PRESS RELEASE for distribution July 6, 2021 Two posters featuring highly significant head to head data for Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) vs Taclonex® Topical Suspension were shown at the Maui Derm NPPA Summer meeting...
by EPI Health | Nov 4, 2020 | Press Release
NEWS PROVIDED BY EPI Health, LLC November 4, 2020 The formulary at Express Scripts and other major PBMs have expanded coverage to include Rhofade® and other EPI Health Products, bringing coverage to over 145 million US Commercial lives. Rhofade®...
by EPI Health | Sep 20, 2020 | Press Release
Express Scripts National Preferred Formulary covers approximately 24 million lives — Rhofade® is the only FDA-approved alpha 1 agonist indicated for the topical treatment of persistent facial erythema associated with rosacea in adults CHARLESTON,...
Recent Comments